Evaluation of the Architect® tacrolimus assay in kidney, liver, and heart transplant recipients

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 4, 2010, Pages 997-1002

  Bazin, Christophe ^a   Guinedor, Amélie ^b   Barau, Caroline ^c   Gozalo, Claire ^d   Grimbert, Philippe ^a   Duvoux, Christophe ^a   Furlan, Valérie ^c   Massias, Laurent ^b   Hulin, Anne ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

CMIA (chemiluminescent microparticle immunoassay); Comparison; Heart liver and kidney transplant recipients; Interferences; Tacrolimus

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACCURACY; ANTIBODY CONJUGATED MAGNETIC IMMUNOASSAY; ARTICLE; CARDIAC GRAFT REJECTION; CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; LIQUID CHROMATOGRAPHY; LIVER GRAFT REJECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; BLOOD; CHEMOLUMINESCENCE; DRUG MONITORING; HEART TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METHODOLOGY;

CHEMILUMINESCENT MEASUREMENTS; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; TACROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 77955588938     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.06.022     Document Type: Article

References (24)

1. Venkataramana R., Shaw L.M., Sarkozi L., Mullins R., Pirsch J., MacFarlane G., Scheller D., Ersfeld D., Frick M., Fitzsimmons W.E., Virji M., Jain A., Brayman K.L., Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J. Clin. Pharmacol. 2001, 41:542-551.
2. Laskow D.A., Vincenti F., Neylan J.F., Mendez R., Matas A.J. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996, 62:900-907.
3. Undre N.A., Stevenson P., Schäfer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant. Proc. 1999, 31:21S-28S.
4. Kershner R.P., Fitzsimmons W.E. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996, 62:920-927.
5. Schwartz M., Holst B., Facklam D., Buell D. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transplant. Proc. 1995, 27:1107-1108.
6. Ekberg H., Tedesco-Silva H., Demirbas A., Vitko S., Nashan B., Gürkan A., Margreiter R., Hugo C., Grinyó J.M., Frei U., Vanrenterghem Y., Daloze P., Halloran P.F. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007, 357:2562-2575.
7. Amann S., Parker T.S., Levine D.M. Evaluation of 2 immunoassays for monitoring low blood levels of tacrolimus. Ther. Drug Monit. 2009, 31:273-276.
8. Oellerich M., Armstrong V.W., Schutz E., Shaw L.M. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin. Biochem. 1998, 31:309-316.
9. Wallemacq P., Armstrong V.W., Brunet M., Haufroid V., Holt D.W., Johnston A., Kuypers D., Meur Y.L., Marquet P., Oellerich M., Thervet E., Toenshoff B., Undre N., Weber L.T., Westley I.S., Mourad M. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 2009, 31:139-152.
10. Wallemacq P., Goffinet J.S., O'Morchoe S., Rosiere T., Maine G.T., Labalette M., Aimo G., Dickson D., Schmidt E., Schwinzer R., Schmid R.W. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther. Drug Monit. 2009, 31:198-204.
11. De B.K., Jimenez E., De S., Sawyer J.C., McMillin G.A. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry and IMx methods. Clin. Chim. Acta. 2009, 410:25-30.
12. Tacrolimus-Architect® System, Abbott Laboratories, 2006.
13. Murthy J.N., Davis D.L., Yatscoff R.W., Soldin S.J. Tacrolimus metabolite cross reactivity in different tacrolimus assays. Clin. Biochem. 1998, 31:613-617.
14. Ansermot N., Fathi M., Veuthey J.L., Desmeules J., Rudaz S., Hochstrasser D. Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. Clin. Biochem. 2008, 41:910-917.
15. Barau C., Frangie C., Goujard C., Tribut O., Parant F., Taburet A.-M., Durrbach A., Furlan V. Falsely elevated whole blood tacrolimus concentrations due to interference in an affinity column-mediated immunoassay method on Xpand dimension. Ther. Drug Monit. 2009, 31:267-268.
16. Hermida J., Tutor T.C. Falsely increased blood tacrolimus concentrations using the ACMIA assay due to circulating endogenous antibodies in a liver transplant recipient: a tentative approach to obtaining reliable results. Ther. Drug Monit. 2009, 31:269-272.
17. Rostaing L., Cointault O., Marquet P., Josse A.G., Lavit M., Saint-Marcoux F., Kamar N. Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards. Transpl. Int. 2009, 22:1056-1059.
18. Altinier S., Varagnolo M., Zaninotto M., Boccagni P., Plebani M. Heterophilic antibody interference in a non-endogenous molecule assay: an apparent elevation in the tacrolimus concentration. Clin. Chim. Acta 2009, 402:193-195.
19. Moscato D., Nonnato A., Adamo R., Vancheri M., Caropreso A. Therapeutic monitoring of Tacrolimus: aberrant results by an immunoassay with automated pretreatment. Clin. Chim. Acta 2010, 411:77-80.
20. Parikh B.A., Siedlecki A.M., Scott M.G. Specificity of a circulating antibody that interferes with a widely used tacrolimus immunoassay. Ther. Drug Monit. 2010, 32:228-231.
21. Griffey M.A., Hock K.G., Kilgore D.C., Wei T.Q., Duh S.-H., Christenson R., Scott M.G. Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyzer. Clin. Chim. Acta 2007, 384:48-54.
22. Ventura E., Bonardet A., Pageaux G.P., Mourad G., Cristol J.P. Calcineurin inhibitor determination in whole blood with the RXL dimension analyzer: a useful tool for immunosuppressive drug monitoring. Transplant. Proc. 2009, 41:707-708.
23. Cavalier E., Carlisi A., Chapelle J.P., Orfanos P., Uzan M., Falque V., Delanaye P., Hachicha M. Human anti-mouse antibodies interferences in Elecsys PTH assay after OKT3 treatment. Transplantation 2009, 87:451-457.
24. Schmid R.W., Lotz J., Schweigert R., Lackner K., Aimo G., Friese J., Rosiere T., Dickson D., Kenney D., Maine G.T. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer. Clin. Biochem. 2009, 42:1543-1548.